ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Balamurali Venkatesan1, Leela Kakithakara Vajravelu1, Sujith Ravi1 , Jayaprakash Thulukanam1 and Om Lokesh Muthamilan2
1SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu – 603203, Tamil Nadu, India.
2Kasturba Medical College, Hampankatta, Mangalore – 575 001, Karnataka, India.
J Pure Appl Microbiol. 2022;16(2):1187-1191 | Article Number: 7596 | © The Author(s). 2022
Received: 04/02/2022 | Accepted: 26/04/2022 | Published online: 31/05/2022
Issue online: June 2022

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) possess high mortality and morbidity across the globe. In India, BBV-152 (CovaxinTM) and ChAdOx1-nCOV (CovishieldTM) vaccines are now being used to limit the spread of SARS-CoV-2 Infection. A Cross sectional observational study was designed to analyze the Antibody immune response to SARS CoV-2 vaccine quantitatively among Health Care Workers and it was correlated with age, sex, other comorbidities and blood group. A total of 160 fully vaccinated HCWs, the Anti-SARS-CoV-2 level was estimated by using Chemiluminescence Immuno Assay. A protective immune response following the complete course of the SARS-CoV-2 vaccine should be ≥ 1.00 S/C. A total of 160 HCWs (82 Male, 78 Female) who had completed both the doses of Covishield (n=128) and Covaxin (n=32). Both the vaccine recipient had mild to moderate symptoms and none of the HCWs had severe adverse events after administration of vaccine. Out of which, 143 (89.3%) HCWs showed seropositive and 17 (10.7%) HCWs showed seronegative. There was no notable variation in sex and other co-morbidities. Significantly, reduced antibody titers towards SARS-CoV-2 vaccine was noted among individuals aged ≤ 60 years and O+ve Blood group. Both the vaccines obtained successful immune response after their complete course, even though there was a significantly higher seropositivity rate in Covishield in spite of Covaxin recipients. Further, genomic correlative advanced studies can conclude the significance of non-responsiveness to SARS-CoV-2 vaccines among the HCWs.


SARS-CoV-2 infection, SARS-CoV-2 Vaccines, Health Care Workers, Antibody immune response to SARS-CoV-2, Non Responsiveness

Article Metrics

Article View: 323

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.